DDMP (2,4-diamino-5-(3',4'-dichlorophenyl)-methylpyrimidine).
D000230:Adenocarcinoma / Q000188:drug therapy; D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism* / Q000633:toxicity; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D003967:Diarrhea / Q000139:chemically induced; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D006258:Head and Neck Neoplasms / Q000188:drug therapy; D006801:Humans; D007928:Lethal Dose 50; D007970:Leukopenia / Q000139:chemically induced; D008175:Lung Neoplasms / Q000188:drug therapy; D008545:Melanoma / Q000188:drug therapy; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy; D011739:Pyrimethamine / Q000031:analogs & derivatives* / Q000378:metabolism / Q000633:toxicity; D051381:Rats; D012640:Seizures / Q000139:chemically induced
D000970:Antineoplastic Agents; C006308:metoprine; D011739:Pyrimethamine